Comunicados de prensa de GSK

Patients had no evidence of cancer following treatment with Jemperli alone, as confirmed by endoscopy, radiology and/or pathology

62% confirmed objective response rate and 12.2-month median duration of response in phase Ib trial

Approval based on phase III data showing unprecedented functional cure rates compared to standard of care

The EMBOLD PanTumour-101 trial showed positive anti-tumour activity and a manageable safety profile.

GSK will present more than 20 abstracts from its expanding solid tumour portfolio at the 2026 ESMO congress

AZUR-1 data showing clinically significant proportion of participants with no detectable signs of cancer one year or more after treatment

For the first time, Viola Davis shares her experience with shingles Viola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come…

Results build on LATITUDE study and robust body of evidence supporting investigational use.

GSK announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager from Chimagen Biosciences.

GSK today announced positive results from the registrational phase I/II ARROS-1 trial

Longer survival achieved with fewer severe treatment-related side effects versus comparator...

New presentation offers convenient administration of GSK's shingles vaccine

Phase III trial to start in September 2026

If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients.

First global approval for Hibsago

Superiority data from LATA together with OPERA findings add to the clinical and real-world evidence base for long-acting injectable Cabenuva

Investment further integrates company into world-class ecosystem of biomedical research, patient care and academia